DEFAR - Departamento de Farmácia

URI permanente desta comunidadehttp://www.hml.repositorio.ufop.br/handle/123456789/530

Navegar

Filtros

20231

Configurações

Autor: search.filters.author.Branquinho, Renata TupinambáAssunto: search.filters.subject.Recurrent vulvovaginal candidiasis

Resultados da Pesquisa

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura Disponível
    Item
    Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis.
    (2023) Teixeira, Aniely dos Reis; Quaresma, Amanda de Vasconcelos; Branquinho, Renata Tupinambá; Santos, Stephanie Lourrani Evangelista Neves; Magalhães, Juliana Teixeira; Silva, Fábio Henrique Rodrigues da; Marques, Maria Betânia de Freitas; Moura, Sandra Aparecida Lima de; Barboza, Ana Paula Moreira; Araújo, Marcelo Gonzaga de Freitas; Silva, Gisele Rodrigues da
    Miconazole-loaded nanoparticles coated with hyaluronic acid (miconazole-loaded nanoparticles/HA) were developed to overcome the limitations of the conventional therapy of the vulvovaginal candidiasis (VVC). They were synthesized by emulsification and solvent evaporation techniques, characterized by diameter, poly- dispersity index, zeta potential, encapsulation efficiency, atomic force microscopy (AFM), evaluated in terms of efficacy against C. albicans in vitro, and tested in a murine VVC model. Nanoparticles showed 211nm of diameter with a 0.32 polydispersity index, -53mV of zeta potential, and 90% miconazole encapsulation efficiency. AFM evidenced nanoparticles with a spherical shape. They inhibited the proliferation of C. albicans in vitro and in vivo after a single administration. Nanoparticles released the miconazole directly in the site of action at low thera- peutic doses, which was enough to eliminate the fungal burden in the murine VVC model. These systems were rationally designed since the existence of the HA induces their adhesion on the vaginal mucus and their inter- nalization via CD44 receptors, inhibiting the C. albicans. Therefore, miconazole-loaded nanoparticles/HA represent an innovative non-conventional pharmaceutical dosage form to treat the VVC and recurrent VVC.